Published in Hospital Law Weekly, January 7th, 2010
NXL 104 inhibits bacterial enzymes called beta-lactamases that break down beta-lactam antibiotics including cephalosporins. It is designed to be co-administered with select antibiotics to enhance their spectrum of activity and counteract bacterial resistance.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.